MAPT and supranuclear palsy, progressive, 1: Although a small sample size, thiscorrelation between PSP-RS and underlying PSP pathology is in keeping with previousstudies.66 In the absence ofa sensitive and specific tau-PET ligand, or indeed any other biomarker, for PSP pathology,there is not an easy way around this clinical–pathological disconnect, and until such timethe inclusion of patients in clinical trials based on a clinical diagnosis of PSP-RS islikely to continue.